Downexpression of HSD17B6 correlates with clinical prognosis and tumor immune infiltrates in hepatocellular carcinoma.
Lei LvYujia ZhaoQinqin WeiYe ZhaoQiyi YiPublished in: Cancer cell international (2020)
This study indicate that HSD17B6 could be a new biomarker for the prognosis of HCC and an important negative regulator of immune responses in HCC.
Keyphrases